Equity Overview
Price & Market Data
Price: $3.99
Daily Change: -$0.141 / 3.52%
Daily Range: $3.91 - $4.12
Market Cap: $28,421,910
Daily Volume: 146,186
Performance Metrics
1 Week: -4.27%
1 Month: -6.89%
3 Months: -49.02%
6 Months: -43.21%
1 Year: -92.27%
YTD: -44.87%
Company Details
Employees: 17
Sector: Health technology
Industry: Biotechnology
Country:
Details
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the
clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.